NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 6 July 2021

**Location:** Via Zoom video conference

## Attendees

Committee members present

1. Dr Jane Adam (Chair) Present for all items
2. Dr Brian Shine (Vice Chair) Present for all items
3. Professor Abdallah Al-Mohammad Present for all items
4. Mr Richard Ballerand Present for all items
5. Dr Andrew Champion Present for all items
6. Dr Justin Daniels Present for all items
7. Dr Steve Edwards Present for all items
8. Dr Rita Faria Present for all items
9. Dr Michael Holmes Present for all items
10. Professor Khalida Ismail Present for all items
11. Ms Sumithra Maheswaran Present for all items
12. Professor G.J. Melendez-Torres Present for all items
13. Mr Hugo Pedder Present for all items
14. Ms Becky Pennington Present for all items
15. Mr Dominic Pivonka Present for all items
16. Ms Pamela Rees Present for all items
17. Dr Mohit Sharma Present for all items
18. Mr Min Ven Teo Present for items1 to 4.2
19. Dr Alice Turner Present for all items
20. Dr Roger Whittaker Present for all items

NICE staff present

Janet Robertson, Associate Director Present for all items

Thomas Feist, Project Manager Present for all items

Mary Hughes, Health Technology Assessment Adviser Present for all items

Summaya Mohammed, Health Technology Assessment Analyst Present for all items

Sarah Wilkes, Health Technology Assessment Analyst Present for all items

Emily Eaton Turner, Technical Adviser, Commercial Risk Assessment Present for items 4.1.3 to 4.2.2

Helen Barnett, Senior Medical Editor Present for all items

Adam Storrow, Business Analyst, Resource Impact Team Present for all items

Nick Cunningham, Coordinator, MIP Present for items

Rosalee Mason, Coordinator, MIP Present for items

Gemma Smith, Coordinator, COT Present for all items

Marcia Miller, Administrator, TA Present for all items

Evidence Review Group representatives present

Charlotta Karner, BMJ TAG Present for items 1 to 4.1.3

Mariana Bacelar, BMJ TAG Present for items 1 to 4.1.3

Clinical & patient experts present

Professor Peter Clark, National Clinical Lead for cancer drugs, NHS England, Present for all items

Dr Mark Verrill, Consultant Medical Oncologist, clinical expert nominated by UK Breast Cancer Group (UKBCG), Present for items 1 to 4.1.3

Holly Heath, Patient expert nominated by Breast Cancer Now, Present for items 1 to 4.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Dr Jane Adam welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted committee member apologies

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 8 June 2021 with 1 minor change.

### Appraisal of abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (ID2727)

* 1. Part 1 – Open session
		1. The chair welcomed the invited clinical and patient experts, the national clinical lead for cancer drugs, external review group representatives, members of the public and company representatives from Eli Lilly.
		2. The chair asked all committee members, clinical and patient experts, the national clinical lead for cancer drugs external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr Abdallah Al-Mohammad declared financial interests as he has received honorarium and advisory board fees from AstraZeneca and Novartis for work relating to heart failure. He also noted that his hospital received a small grant from AstraZeneca to purchase blood pressure machines to give to patients with heart failure to enable the heart failure nurses to remotely up-titrate the medication in view of the COVID-19 restrictions. None of the interests relate to breast cancer.
* It was agreed that his declaration would not prevent Dr Al-Mohammad from participating in this section of the meeting.
* Committee member Dr Steve Edwards is also part of the ERG team who carried out the assessment for this appraisal and therefore as a direct conflict Dr Edwards did not attend the meeting for this topic.
* Nominated clinical expert Dr Mark Verrill declared direct financial interests as he has previously received honoraria from Eli Lilly, Novartis, Pfizer and Daichii Sankyo for speaker fees and advisory boards. He has also received funding for studies of breast cancer treatments.
* It was agreed that his declaration would not prevent Dr Verrill from providing expert advice to the committee.
* Nominated patient expert Holly Heath declared an indirect financial interest as her employer, Breast Cancer Now, has received funding from Novartis and Eli Lilly. The funding was not related to policy and campaign work. It was agreed that her declaration would not prevent Holly from providing expert advice to the committee.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 – Closed session (company representatives, clinical and patient experts, external review group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Documentation (FAD). The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Documentation (FAD) in line with their decisions.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on 3 August 2021 and will start promptly at 9:30am.